The study of the state of pharmaceutical provision for patients with cardiovascular diseases using ABC- and VEN-analyses
Keywords:complex ABC/VEN analysis, medicines, cardiovascular diseases, government program, pharmacoeconomics
Aim. To assess the state of pharmaceutical provision for patients with cardiovascular diseases (CVD) using ABC, VEN and complex ABC/VEN analyses.
Materials and methods. The study was performed according to the data of the medical records of outpatients who were registered in the Public Health Institution (PSI) “Kharkiv City Clinical Hospital No. 27”. The methods of ABC, VEN and complex ABC/VEN analysis were used.
Results and discussion. The results of the study using the ABC-analysis method allowed us to determine that the largest number of drugs was in the group C, which included 25 drugs, or 51.02 % of the total number of prescriptions. During the VEN analysis it was found that the vast majority of drugs (41 drugs) belong to the group V – vital essential medicines. The complex ABC/VEN analysis showed that drugs with the A/V status (the most costly and vital essential medicines) had the highest percentage (32.20 %) of the total consumption. It should be separately noted that the A/N group (the most costly and nonessential medicines) took the second position by percentage after the A/V group. A high percentage (31.05 %) in the A/N group is explained by the fact that the group includes the drug Magnikor, which has the highest frequency of prescription although this drug is not included in the National List of Essential Medicines (NLEM) and in the “Available medicines” program.
Conclusions. The results of the studies of the state of pharmaceutical care for patients with CVD make it possible to draw attention to the urgency of the problems of drug availability to the population, namely expanding the list of medicines that are reimbursed in the framework of the government programs, in particular by including the drug Magnikor in the “Available medicines” program.
European Cardiovascular Disease Statistics.(2017). ehnheart.org. Retrieved from: http://www.ehnheart.org/cvd-statistics.html
Dostupniliky. [Available medicines]. liky.gov.ua. Retrieved from: http://liky.gov.ua/
Reiestr optovo-vidpusknykh tsinnalikarskizasoby MOZ Ukrainy. moz.gov.ua. Retrieved from: http://www.moz.gov.ua/ua/portal/register_prices_drugs/
Ofitsiinyi sait Kabinetu ministriv Ukrainy. kmu.gov.ua. Retrieved from: https://www.kmu.gov.ua/ua
Bezditko, N. V., Chynush, I. V. (2012). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (24), 54–59.
Vorobev, P.A. (2008). Ratcionalnaia farmakoterapiia, 1 (10), 5–14.
Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V., Mishchenko, O. Ya., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Chynush, I. V. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno–profilaktychnomu zakladi (suprovid formuliarnoi systemy): metodychni rekomendatsii. Kiev, 36.
ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems. (2008). American Journal of Health-System Pharmacy, 65(14), 1368–1384. https://doi.org/10.2146/ajhp080021
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).